Luciano Costa MD, PhD, on the MASTER Trial and MRD Considerations in MM

In this episode of “Blood Cancer Talks,” Luciano Costa MD, PhD, of the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, joins the show to provide listeners with an overview of measurable residual disease (MRD) in multiple myeloma (MM).

Dr. Costa speaks about the use of MRD as a prognostic biomarker, as well as how it can be used as a tool to adapt therapy, and its use as a surrogate clinical trial endpoint. He also discusses the MASTER trial, which was the first to test an MRD-adapted treatment strategy in MM.